A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry
Abstract Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody that targets the IL-6 receptor. TCZ found to be efficacious and has a good tolerated safety profile in rheumatoid arthritis (RA) patients. The aim of this study was to describe the disease activity and retention rate in Turkis...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-12-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-26106-0 |
| _version_ | 1797977453048627200 |
|---|---|
| author | Ayten Yazici Özlem Özdemir Işık Ediz Dalkılıç Süleyman Serdar Koca Yavuz Pehlivan Soner Şenel Nevsun Inanc Servet Akar Sema Yılmaz Özgül Soysal Gündüz Ayse Cefle Ömer Fatih Karakaş Fatos Onen |
| author_facet | Ayten Yazici Özlem Özdemir Işık Ediz Dalkılıç Süleyman Serdar Koca Yavuz Pehlivan Soner Şenel Nevsun Inanc Servet Akar Sema Yılmaz Özgül Soysal Gündüz Ayse Cefle Ömer Fatih Karakaş Fatos Onen |
| author_sort | Ayten Yazici |
| collection | DOAJ |
| description | Abstract Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody that targets the IL-6 receptor. TCZ found to be efficacious and has a good tolerated safety profile in rheumatoid arthritis (RA) patients. The aim of this study was to describe the disease activity and retention rate in Turkish RA patients who were prescribed TCZ as first-line biologic treatment in a real-world setting. Secondary data obtained from adult RA patients’ files was used in a multicenter and retrospective context. Clinical Disease Activity Index (CDAI), Disease Activity Score in 28 joints with ESR (DAS28-ESR), and retention rates of TCZ were evaluated at related time points. 130 patients (87.7% female) with a mean age of 53 years (SD; 15.0) were included in the study. Mean RA duration was 14 years and median duration of follow-up was 18.5 months. Number of patients with ongoing TCZ treatment at 6, 12, and 24 months were 121 (93%), 85 (65%), and 46 (35%), respectively. Remission rates at 6, 12, and 24 months per CDAI (< 2.8) and DAS28-ESR (< 2.6) scores were 61.5, 44.6, 30%, and 54.6, 40.8, 27.7%, respectively. Both CDAI and DAS28-ESR scores significantly improved at 6, 12 and 24 months (p < 0.001 for both). At 24 months, 23 patients (17.6%) discontinued TCZ, of whom majority (17/23) were due to unsatisfactory response. Retention rates of TCZ at 6, 12, and 24 months were 93, 84.3, and 72.2%, respectively. In this real-world study, TCZ as a first-line biologic therapy was found to be efficacious and showing high retention rates. These real-world study results are in line with previous randomized studies. |
| first_indexed | 2024-04-11T05:07:07Z |
| format | Article |
| id | doaj.art-19120a1a963b4c70ac0f49b9a53e4fb6 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-11T05:07:07Z |
| publishDate | 2022-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-19120a1a963b4c70ac0f49b9a53e4fb62022-12-25T12:13:13ZengNature PortfolioScientific Reports2045-23222022-12-011211710.1038/s41598-022-26106-0A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registryAyten Yazici0Özlem Özdemir Işık1Ediz Dalkılıç2Süleyman Serdar Koca3Yavuz Pehlivan4Soner Şenel5Nevsun Inanc6Servet Akar7Sema Yılmaz8Özgül Soysal Gündüz9Ayse Cefle10Ömer Fatih Karakaş11Fatos Onen12Department of Internal Medicine Division of Rheumatology, Kocaeli University Faculty of MedicineDepartment of Internal Medicine Division of Rheumatology, Kocaeli University Faculty of MedicineDepartment of Internal Medicine Division of Rheumatology, Uludağ University Faculty of MedicineDepartment of Internal Medicine Division of Rheumatology, Fırat University Faculty of MedicineDepartment of Internal Medicine Division of Rheumatology, Uludağ University Faculty of MedicineDepartment of Internal Medicine Division of Rheumatology, Erciyes University Faculty of MedicineDepartment of Internal Medicine Division of Rheumatology, Marmara University Faculty of MedicineDepartment of Internal Medicine Division of Rheumatology, Katip Çelebi University Faculty of MedicineDepartment of Internal Medicine Division of Rheumatology, Selçuk University Faculty of MedicineDepartment of Internal Medicine Division of Rheumatology, Celal Bayar University Faculty of MedicineDepartment of Internal Medicine Division of Rheumatology, Kocaeli University Faculty of MedicineRoche TurkeyDepartment of Internal Medicine Division of Rheumatology, Dokuz Eylül University Faculty of MedicineAbstract Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody that targets the IL-6 receptor. TCZ found to be efficacious and has a good tolerated safety profile in rheumatoid arthritis (RA) patients. The aim of this study was to describe the disease activity and retention rate in Turkish RA patients who were prescribed TCZ as first-line biologic treatment in a real-world setting. Secondary data obtained from adult RA patients’ files was used in a multicenter and retrospective context. Clinical Disease Activity Index (CDAI), Disease Activity Score in 28 joints with ESR (DAS28-ESR), and retention rates of TCZ were evaluated at related time points. 130 patients (87.7% female) with a mean age of 53 years (SD; 15.0) were included in the study. Mean RA duration was 14 years and median duration of follow-up was 18.5 months. Number of patients with ongoing TCZ treatment at 6, 12, and 24 months were 121 (93%), 85 (65%), and 46 (35%), respectively. Remission rates at 6, 12, and 24 months per CDAI (< 2.8) and DAS28-ESR (< 2.6) scores were 61.5, 44.6, 30%, and 54.6, 40.8, 27.7%, respectively. Both CDAI and DAS28-ESR scores significantly improved at 6, 12 and 24 months (p < 0.001 for both). At 24 months, 23 patients (17.6%) discontinued TCZ, of whom majority (17/23) were due to unsatisfactory response. Retention rates of TCZ at 6, 12, and 24 months were 93, 84.3, and 72.2%, respectively. In this real-world study, TCZ as a first-line biologic therapy was found to be efficacious and showing high retention rates. These real-world study results are in line with previous randomized studies.https://doi.org/10.1038/s41598-022-26106-0 |
| spellingShingle | Ayten Yazici Özlem Özdemir Işık Ediz Dalkılıç Süleyman Serdar Koca Yavuz Pehlivan Soner Şenel Nevsun Inanc Servet Akar Sema Yılmaz Özgül Soysal Gündüz Ayse Cefle Ömer Fatih Karakaş Fatos Onen A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry Scientific Reports |
| title | A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry |
| title_full | A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry |
| title_fullStr | A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry |
| title_full_unstemmed | A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry |
| title_short | A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry |
| title_sort | national multicenter secondary data use study evaluating efficacy and retention of first line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real life setting results from turkbio registry |
| url | https://doi.org/10.1038/s41598-022-26106-0 |
| work_keys_str_mv | AT aytenyazici anationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT ozlemozdemirisık anationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT edizdalkılıc anationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT suleymanserdarkoca anationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT yavuzpehlivan anationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT sonersenel anationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT nevsuninanc anationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT servetakar anationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT semayılmaz anationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT ozgulsoysalgunduz anationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT aysecefle anationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT omerfatihkarakas anationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT fatosonen anationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT aytenyazici nationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT ozlemozdemirisık nationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT edizdalkılıc nationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT suleymanserdarkoca nationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT yavuzpehlivan nationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT sonersenel nationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT nevsuninanc nationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT servetakar nationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT semayılmaz nationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT ozgulsoysalgunduz nationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT aysecefle nationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT omerfatihkarakas nationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry AT fatosonen nationalmulticentersecondarydatausestudyevaluatingefficacyandretentionoffirstlinebiologictreatmentwithtocilizumabinpatientswithrheumatoidarthritisinreallifesettingresultsfromturkbioregistry |